Immunic (IMUX) Payables (2013 - 2026)

Immunic has reported Payables for 14 years, with the latest figure at $11.0 million in Q1 2026.

• Quarterly Payables rose 83.18% year-over-year to $11.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.0 million (up 83.18% YoY) and the FY2025 annual result came in at $10.1 million, up 29.21% from the prior year.
• Payables rose to $11.0 million in Q1 2026 per IMUX's latest filing, from $10.1 million in the prior quarter.
• Over five years, Payables peaked at $11.0 million in Q1 2026 and troughed at $3.2 million in Q3 2023.
• A 5-year average of $6.2 million and a median of $6.0 million in 2025 frame the typical range for Payables.
• The sharpest annual moves came in 2022 and 2024: Payables tumbled 67.28% in 2022, then jumped 88.87% in 2024.
• Over 5 years, Payables stood at $4.3 million in 2022, then increased by 19.11% to $5.1 million in 2023, then soared by 53.87% to $7.8 million in 2024, then gained by 29.21% to $10.1 million in 2025, then climbed by 8.61% to $11.0 million in 2026.
• According to Business Quant data, Payables over the past three periods registered $11.0 million, $10.1 million, and $7.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.